Accelerate Diagnostics (NASDAQ:AXDX) Stock Rating Upgraded by StockNews.com

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Monday.

Accelerate Diagnostics Stock Performance

NASDAQ:AXDX remained flat at $1.64 during midday trading on Monday. 67,064 shares of the company traded hands, compared to its average volume of 81,425. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $5.23. The company’s fifty day simple moving average is $1.79 and its 200 day simple moving average is $1.51. The company has a market capitalization of $41.07 million, a price-to-earnings ratio of -0.57 and a beta of 0.59.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics at the end of the most recent quarter. Hedge funds and other institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.